Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
narcolepsy
Pharma
China biotech deals, Takeda, LaNova—Fierce Pharma Asia
Biotech deals originating out of China are surging. Takeda touts a pair of OX2R phase 3 wins. Merck's PD-1xVEGF partner is being acquired. And more.
Angus Liu
Jul 18, 2025 9:04am
Axsome will begin trial this year in MDD with daytime sleepiness
Apr 1, 2025 4:40pm
JPM25: Takeda touts 6 pipeline assets with big sales potential
Jan 15, 2025 3:17pm
After trial win, Axsome eyes FDA filing for narcolepsy hopeful
Nov 27, 2024 9:46am
Takeda, WuXi, LianBio—Fierce Pharma Asia
Feb 16, 2024 8:24am
Drug mix-up prompts Azurity to recall 1 lot of Zenzedi
Jan 26, 2024 9:41am
